Last 12 months
Inside the activity.
6 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 1 | 0 |
| Feb 2026 | 2 | 0 |
| Mar 2026 | 0 | 6 |
| Apr 2026 | 2 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 13, 2021 Filed Dec 15, 2021 23:34 UTC |
Salvadori Daniel Gesua SiveEXECUTIVE VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 31,229 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001415889-21-005967 · form4-12152021_031216.xml · derivative · entry 6 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,803 Underlying: Common Shares · 31,229 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 23:34 UTC |
Salvadori Daniel Gesua SiveEXECUTIVE VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 23,771 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001415889-21-005967 · form4-12152021_031216.xml · derivative · entry 5 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,542 Underlying: Common Shares · 23,771 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 23:34 UTC |
Salvadori Daniel Gesua SiveEXECUTIVE VICE PRESIDENT
|
SaleCommon shares without par value | 55,000 | $135.00 | $7,425,000.00 |
DisclosureSEC source: 0001415889-21-005967 · form4-12152021_031216.xml · nonDerivative · entry 4 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,931 Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 23:34 UTC |
Salvadori Daniel Gesua SiveEXECUTIVE VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 31,229 | $44.40 | $1,386,567.60 |
DisclosureSEC source: 0001415889-21-005967 · form4-12152021_031216.xml · nonDerivative · entry 3 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 23:34 UTC |
Salvadori Daniel Gesua SiveEXECUTIVE VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 23,771 | $38.40 | $912,806.40 |
DisclosureSEC source: 0001415889-21-005967 · form4-12152021_031216.xml · nonDerivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,702 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 23:34 UTC |
Salvadori Daniel Gesua SiveEXECUTIVE VICE PRESIDENT
|
SaleCommon shares without par value | 3,499 | $135.00 | $472,365.00 |
DisclosureSEC source: 0001415889-21-005967 · form4-12152021_031216.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,931 Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 23:38 UTC |
Wainer Andrea FEXECUTIVE VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 7,500 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001415889-21-005968 · form4-12152021_031202.xml · derivative · entry 5 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 7,500 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 23:38 UTC |
Wainer Andrea FEXECUTIVE VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 7,000 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001415889-21-005968 · form4-12152021_031202.xml · derivative · entry 4 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,726 Underlying: Common Shares · 7,000 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 23:38 UTC |
Wainer Andrea FEXECUTIVE VICE PRESIDENT
|
SaleCommon shares without par value | 14,500 | $135.00 | $1,957,500.00 |
DisclosureSEC source: 0001415889-21-005968 · form4-12152021_031202.xml · nonDerivative · entry 3 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,782 Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 23:38 UTC |
Wainer Andrea FEXECUTIVE VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 7,500 | $38.40 | $288,000.00 |
DisclosureSEC source: 0001415889-21-005968 · form4-12152021_031202.xml · nonDerivative · entry 2 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 23:38 UTC |
Wainer Andrea FEXECUTIVE VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 7,000 | $47.00 | $329,000.00 |
DisclosureSEC source: 0001415889-21-005968 · form4-12152021_031202.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2021 Filed Dec 8, 2021 22:25 UTC |
Morrone Louis H.SENIOR VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 9,988 | $0.00 Strike: $48.34 | $0.00 |
DisclosureSEC source: 0001415889-21-005787 · form4-12082021_021237.xml · derivative · entry 7 Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,988 Underlying: Common Shares · 9,988 shares Expires 2027-07-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 07, 2021 Filed Dec 8, 2021 22:25 UTC |
Morrone Louis H.SENIOR VICE PRESIDENT
|
SaleCommon shares without par value | 9,988 | $134.00 | $1,338,392.00 |
DisclosureSEC source: 0001415889-21-005787 · form4-12082021_021237.xml · nonDerivative · entry 4 Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,229 Read SEC document |
| December 07, 2021 Filed Dec 8, 2021 22:25 UTC |
Morrone Louis H.SENIOR VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 9,988 | $48.34 | $482,819.92 |
DisclosureSEC source: 0001415889-21-005787 · form4-12082021_021237.xml · nonDerivative · entry 3 Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,217 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 22:25 UTC |
Morrone Louis H.SENIOR VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 9,989 | $0.00 Strike: $48.34 | $0.00 |
DisclosureSEC source: 0001415889-21-005787 · form4-12082021_021237.xml · derivative · entry 6 Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,976 Underlying: Common Shares · 9,989 shares Expires 2027-07-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 22:25 UTC |
Morrone Louis H.SENIOR VICE PRESIDENT
|
SaleCommon shares without par value | 9,989 | $131.01 | $1,308,683.86 |
DisclosureSEC source: 0001415889-21-005787 · form4-12082021_021237.xml · nonDerivative · entry 2 Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,229 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.00 to $131.16, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 22:25 UTC |
Morrone Louis H.SENIOR VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 9,989 | $48.34 | $482,868.26 |
DisclosureSEC source: 0001415889-21-005787 · form4-12082021_021237.xml · nonDerivative · entry 1 Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 22:29 UTC |
Wainer Andrea FEXECUTIVE VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 4,500 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001415889-21-005788 · form4-12082021_021227.xml · derivative · entry 3 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,726 Underlying: Common Shares · 4,500 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 22:29 UTC |
Wainer Andrea FEXECUTIVE VICE PRESIDENT
|
SaleCommon shares without par value | 4,500 | $132.50 | $596,250.00 |
DisclosureSEC source: 0001415889-21-005788 · form4-12082021_021227.xml · nonDerivative · entry 2 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,782 Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 22:29 UTC |
Wainer Andrea FEXECUTIVE VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 4,500 | $47.00 | $211,500.00 |
DisclosureSEC source: 0001415889-21-005788 · form4-12082021_021227.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:11 UTC |
Ahlberg Gregory ASENIOR VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 30,935 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001415889-21-005270 · form4-11172021_031105.xml · derivative · entry 7 Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,468 Underlying: Common Shares · 30,935 shares Expires 2028-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:11 UTC |
Ahlberg Gregory ASENIOR VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 6,000 | $0.00 Strike: $48.98 | $0.00 |
DisclosureSEC source: 0001415889-21-005270 · form4-11172021_031105.xml · derivative · entry 6 Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 6,000 shares Expires 2027-08-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:11 UTC |
Ahlberg Gregory ASENIOR VICE PRESIDENT
|
SaleCommon shares without par value | 21,568 | $130.00 | $2,803,840.00 |
DisclosureSEC source: 0001415889-21-005270 · form4-11172021_031105.xml · nonDerivative · entry 4 Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,287 Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:11 UTC |
Ahlberg Gregory ASENIOR VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 30,935 | $59.94 | $1,854,243.90 |
DisclosureSEC source: 0001415889-21-005270 · form4-11172021_031105.xml · nonDerivative · entry 3 Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,855 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:11 UTC |
Ahlberg Gregory ASENIOR VICE PRESIDENT
|
SaleCommon shares without par value | 3,905 | $130.00 | $507,650.00 |
DisclosureSEC source: 0001415889-21-005270 · form4-11172021_031105.xml · nonDerivative · entry 2 Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,920 Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:11 UTC |
Ahlberg Gregory ASENIOR VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 6,000 | $48.98 | $293,880.00 |
DisclosureSEC source: 0001415889-21-005270 · form4-11172021_031105.xml · nonDerivative · entry 1 Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:18 UTC |
Wainer Andrea FEXECUTIVE VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 7,500 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001415889-21-005271 · form4-11172021_031149.xml · derivative · entry 5 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Shares · 7,500 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:18 UTC |
Wainer Andrea FEXECUTIVE VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 5,000 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001415889-21-005271 · form4-11172021_031149.xml · derivative · entry 4 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,226 Underlying: Common Shares · 5,000 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:18 UTC |
Wainer Andrea FEXECUTIVE VICE PRESIDENT
|
SaleCommon shares without par value | 12,500 | $130.01 | $1,625,111.25 |
DisclosureSEC source: 0001415889-21-005271 · form4-11172021_031149.xml · nonDerivative · entry 3 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,782 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.00 to $130.03, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:18 UTC |
Wainer Andrea FEXECUTIVE VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 7,500 | $38.40 | $288,000.00 |
DisclosureSEC source: 0001415889-21-005271 · form4-11172021_031149.xml · nonDerivative · entry 2 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:18 UTC |
Wainer Andrea FEXECUTIVE VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 5,000 | $47.00 | $235,000.00 |
DisclosureSEC source: 0001415889-21-005271 · form4-11172021_031149.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:22 UTC |
LANE ANDREW HEXECUTIVE VICE PRESIDENT
|
SaleCommon shares without par value | 10,000 | $130.01 | $1,300,090.00 |
DisclosureSEC source: 0001415889-21-005272 · form4-11172021_031122.xml · nonDerivative · entry 1 LANE ANDREW H · CIK 0001643735 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,087 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.00 to $130.03, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 12, 2021 Filed Dec 8, 2021 22:36 UTC |
WHITE MILES DDirector · EXECUTIVE CHAIRMAN
|
GiftCommon shares without par value | 10,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-005789 · form4-12082021_021228.xml · nonDerivative · entry 2 WHITE MILES D · CIK 0001239129 · Director · EXECUTIVE CHAIRMAN 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,092,852 Read SEC document |
| November 10, 2021 Filed Dec 8, 2021 22:36 UTC |
WHITE MILES DDirector · EXECUTIVE CHAIRMAN
|
GiftCommon shares without par value | 693 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-005789 · form4-12082021_021228.xml · nonDerivative · entry 1 WHITE MILES D · CIK 0001239129 · Director · EXECUTIVE CHAIRMAN 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,103,252 Read SEC document |
| October 27, 2021 Filed Oct 27, 2021 22:45 UTC |
Ginascol John FEXECUTIVE VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 45,709 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001415889-21-004998 · form4-10272021_031009.xml · derivative · entry 3 Ginascol John F · CIK 0001778075 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 45,709 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| October 27, 2021 Filed Oct 27, 2021 22:45 UTC |
Ginascol John FEXECUTIVE VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 29,588 | $128.13 | $3,791,110.44 |
DisclosureSEC source: 0001415889-21-004998 · form4-10272021_031009.xml · nonDerivative · entry 2 Ginascol John F · CIK 0001778075 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,674 Read SEC document |
| October 27, 2021 Filed Oct 27, 2021 22:45 UTC |
Ginascol John FEXECUTIVE VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 45,709 | $47.00 | $2,148,323.00 |
DisclosureSEC source: 0001415889-21-004998 · form4-10272021_031009.xml · nonDerivative · entry 1 Ginascol John F · CIK 0001778075 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,262 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 26, 2021 Filed Oct 27, 2021 22:37 UTC |
OSBORN WILLIAM ADirector
|
Exercise / conversionOption (right to buy) · Derivative | 15,752 | $0.00 Strike: $59.42 | $0.00 |
DisclosureSEC source: 0001415889-21-004997 · form4-10272021_031001.xml · derivative · entry 2 OSBORN WILLIAM A · CIK 0001171797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 15,752 shares Expires 2028-04-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| October 26, 2021 Filed Oct 27, 2021 22:37 UTC |
OSBORN WILLIAM ADirector
|
Exercise / conversionCommon shares without par value | 15,752 | $59.42 | $935,983.84 |
DisclosureSEC source: 0001415889-21-004997 · form4-10272021_031001.xml · nonDerivative · entry 1 OSBORN WILLIAM A · CIK 0001171797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,996 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 25, 2021 Filed Oct 27, 2021 22:22 UTC |
Boudreau Philip PVICE PRESIDENT
|
SaleCommon shares without par value | 8,000 | $126.49 | $1,011,920.00 |
DisclosureSEC source: 0001415889-21-004996 · form4-10272021_031057.xml · nonDerivative · entry 1 Boudreau Philip P · CIK 0001805099 · VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,876 Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:07 UTC |
Ahlberg Gregory ASENIOR VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 220 | $118.13 | $25,988.60 |
DisclosureSEC source: 0001415889-21-004754 · form4-10052021_021021.xml · nonDerivative · entry 1 Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,825 Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 21:27 UTC |
Alpern Robert JDirector
|
GrantStock Equivalent Units · Derivative | 66 | $118.13 | $7,796.58 |
DisclosureSEC source: 0001415889-21-004707 · form4-10042021_021007.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,505 Underlying: Common Shares · 66 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 21:35 UTC |
Gonzalez Patricia PaolaDirector
|
GrantStock Equivalent Units · Derivative | 88 | $118.13 | $10,395.44 |
DisclosureSEC source: 0001415889-21-004712 · form4-10042021_021034.xml · derivative · entry 1 Gonzalez Patricia P. · CIK 0001879701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88 Underlying: Common Shares · 88 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 21:41 UTC |
Roman Michael FDirector
|
GrantStock Equivalent Units · Derivative | 279 | $118.13 | $32,958.27 |
DisclosureSEC source: 0001415889-21-004715 · form4-10042021_021035.xml · derivative · entry 1 Roman Michael F · CIK 0001577544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 469 Underlying: Common Shares · 279 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 21:46 UTC |
Stratton John GDirector
|
GrantStock Equivalent Units · Derivative | 279 | $118.13 | $32,958.27 |
DisclosureSEC source: 0001415889-21-004717 · form4-10042021_021024.xml · derivative · entry 1 Stratton John G · CIK 0001385262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,958 Underlying: Common Shares · 279 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 08, 2021 Filed Sep 10, 2021 22:13 UTC |
PEDERSON MICHAEL JSENIOR VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 23,008 | $0.00 Strike: $50.72 | $0.00 |
DisclosureSEC source: 0001415889-21-004350 · form4-09102021_030923.xml · derivative · entry 4 PEDERSON MICHAEL J · CIK 0001712233 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 23,008 shares Expires 2027-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 08, 2021 Filed Sep 10, 2021 22:13 UTC |
PEDERSON MICHAEL JSENIOR VICE PRESIDENT
|
SaleCommon shares without par value | 23,008 | $129.05 | $2,969,173.20 |
DisclosureSEC source: 0001415889-21-004350 · form4-09102021_030923.xml · nonDerivative · entry 2 PEDERSON MICHAEL J · CIK 0001712233 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,571 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.03 to $129.09, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 08, 2021 Filed Sep 10, 2021 22:13 UTC |
PEDERSON MICHAEL JSENIOR VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 23,008 | $50.72 | $1,166,965.76 |
DisclosureSEC source: 0001415889-21-004350 · form4-09102021_030923.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2021 Filed Sep 8, 2021 21:28 UTC |
WOODGRIFT RANDEL WILLIAMSENIOR VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 1,000 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001415889-21-004285 · form4-09082021_020912.xml · derivative · entry 5 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,333 Underlying: Common Shares · 1,000 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 03, 2021 Filed Sep 8, 2021 21:28 UTC |
WOODGRIFT RANDEL WILLIAMSENIOR VICE PRESIDENT
|
SaleCommon shares without par value | 5,350 | $129.00 | $690,150.00 |
DisclosureSEC source: 0001415889-21-004285 · form4-09082021_020912.xml · nonDerivative · entry 3 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,743 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.